Evidence method
Level · gp.fundamentals.debt_to_revenue
37.96% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
WST · Mar 31, 2021
WEST PHARMACEUTICAL SERVICES INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000105770-21-000026General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
8.16% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
13.22% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
36.46% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
46.25% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
40.54% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
26.18% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
1.82% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
0.88% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History39 statesSelf-history eligible
Mar 31, 201910/10 normalizedLevel 3Jun 30, 201910/10 normalizedLevel 3Sep 30, 201910/10 normalizedLevel 3Dec 31, 20198/8 normalizedLevel 3Mar 31, 20209/9 normalizedLevel 3Jun 30, 20209/9 normalizedLevel 3Sep 30, 20209/9 normalizedLevel 3Dec 31, 20209/9 normalizedLevel 3Mar 31, 20219/9 normalizedLevel 3Jun 30, 20219/9 normalizedLevel 3Sep 30, 20219/9 normalizedLevel 3Dec 31, 20219/9 normalizedLevel 3Mar 31, 20229/9 normalizedLevel 3Jun 30, 20229/9 normalizedLevel 3Sep 30, 20229/9 normalizedLevel 3Dec 31, 20229/9 normalizedLevel 3Mar 31, 20239/9 normalizedLevel 3Jun 30, 20239/9 normalizedLevel 3Sep 30, 20239/9 normalizedLevel 3Sep 30, 20269/9 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 11.89%
- Current
- 37.96%
- Delta
- 26.07%
- Previous
- 8.12%
- Current
- 8.16%
- Delta
- 0.03%
- Previous
- 22.01%
- Current
- 13.22%
- Delta
- -8.78%
- Previous
- 16.69%
- Current
- 36.46%
- Delta
- 19.77%
- Previous
- 14.97%
- Current
- 46.25%
- Delta
- 31.28%
- Previous
- 35.76%
- Current
- 40.54%
- Delta
- 4.78%
- Previous
- 18.95%
- Current
- 26.18%
- Delta
- 7.23%
- Previous
- 2.18%
- Current
- 1.82%
- Delta
- -0.37%
- Previous
- 1.58%
- Current
- 0.88%
- Delta
- -0.70%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · WST Fundamental State →Analogous To · WST state analogue 4 →Has State · WEST PHARMACEUTICAL SERVICES INC →Transitioned To · WST Fundamental State →Transitioned To · WST BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · WST CAPEX_INTENSITY_INCREASED →Transitioned To · WST CASH_GENERATION_DECREASED →Transitioned To · WST GROWTH_INCREASED →Transitioned To · WST INVENTORY_PRESSURE_INCREASED →Transitioned To · WST MARGIN_INCREASED →Transitioned To · WST PROFITABILITY_INCREASED →Transitioned To · WST R_AND_D_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.